AstraZeneca sells US rights to RSV drug for $1.5bn
AstraZeneca announced it will sell US rights to Synagis to Sobi, to focus on its collaborative RSV therapy.
Archives for November 14, 2018
US FDA warning: Illegally marketed stem cell therapy made in substandard lab
California-based StemGenex marketed its SVF drug without an approved biologics license application, according to the agency.
BIO EUROPE 2018
BIO: Trump’s Part B pricing scheme ‘undermines the incentive to innovate’
We will not stand behind non-competitive pricing schemes that undermine the incentive to innovate and invest in drug development, says BIO VP of industry research, David Thomas.